Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : CEO promises to speed data integrity disclosures

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2019 | 09:41am EDT
FILE PHOTO: CEO Vas Narasimhan of Swiss drugmaker Novartis addresses the company's annual news conference in Basel

ZURICH (Reuters) - Novartis Chief Executive Vas Narasimhan, facing an uproar over data manipulation involving $2.1 million gene therapy Zolgensma, pledged on Monday to tell regulators quickly if credible questions emerge in future over data integrity.

Novartis has said it knew of discrepancies in Zolgensma data it had submitted to the U.S. Food and Drug Administration before it won approval for the world's most expensive medicine in May, but delayed informing regulators until June 28 while it completed an internal investigation.

While the FDA has concluded Zolgensma is safe and effective and should remain on the market, the U.S. drug watchdog raised questions about the timing of Novartis's disclosure. U.S. senators have also demanded the Swiss drugmaker explain why it took so long to inform the agency.

Novartis could face possible civil or criminal penalties, the FDA has said. Zolgensma treats spinal muscular atrophy, the leading genetic cause of death in infants.

"We are making a voluntary commitment to notify the FDA within five business days of receipt by our quality (control) organization of any credible allegation related to data integrity impacting any pending application in the Novartis Group," Narasimhan said at an investor event, adding Novartis will take a similar approach in other jurisdictions.

Novartis said it gave "detailed explanations" on Aug. 23 to the FDA about the company's investigation into the data manipulation, and addressed regulators' questions over why the company waited until late June to make disclosures.

The company has said it has "exited" scientists it identified in its data manipulation probe. One of those scientists, Brian Kaspar, through his lawyer, has denied wrongdoing.

During Monday's investor event on corporate governance, Narasimhan said the Basel-based company has countless instances where its employees must use judgment about how to manage potential problems that crop up with its drugs, but that the tumult surrounding Zolgensma prompted it to change its practices.

"What we realized through this situation is, during a filing, it's difficult for us to exercise that judgment without it being later considered maybe not the best judgment," Narasimhan said. "So we're just taking judgment out of that equation" with the new five-day rule.

(Reporting by John Miller; Editing by Michael Shields)

By John Miller

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
07:07aNOVARTIS : Initiation of Novartis Entresto in-hospital included in the new ACC E..
AQ
01:31aNOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) -2-
DJ
01:31aNOVARTIS : CHF0.50(REGD) Novartis Cosentyx(R) Positive 16-week Prevent Results A..
DJ
09/16NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
AQ
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
09/13NOVARTIS : The Startup That Manipulated Data to Get a Miracle Drug to Market
DJ
09/13NOVARTIS : The Startup That Manipulated Data to Get a -2-
DJ
09/13NOVARTIS : New Novartis data show Mayzent can help preserve mobility for longer ..
AQ
09/13NOVARTIS : New Novartis data show that neuronal and glial filaments, biomarkers ..
PU
More news
Financials (USD)
Sales 2019 47 014 M
EBIT 2019 13 827 M
Net income 2019 10 117 M
Debt 2019 17 463 M
Yield 2019 3,43%
P/E ratio 2019 18,6x
P/E ratio 2020 20,3x
EV / Sales2019 4,59x
EV / Sales2020 4,23x
Capitalization 198 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,49  $
Last Close Price 86,44  $
Spread / Highest target 24,3%
Spread / Average Target 9,31%
Spread / Lowest Target -5,70%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS16.65%198 073
JOHNSON & JOHNSON1.34%341 878
ROCHE HOLDING LTD.12.28%234 825
MERCK AND COMPANY7.36%210 028
PFIZER-15.62%203 709
AMGEN-0.30%116 390